The stock of Puma Biotechnology Inc (NYSE:PBYI) is a huge mover today! The stock decreased 4.23% or $1.9 during the last trading session, hitting $43.05. About 473,755 shares traded hands. Puma Biotechnology Inc (NYSE:PBYI) has risen 39.25% since April 27, 2016 and is uptrending. It has outperformed by 34.02% the S&P500.
The move comes after 6 months negative chart setup for the $1.60B company. It was reported on Nov, 30 by Barchart.com. We have $39.61 PT which if reached, will make NYSE:PBYI worth $128.00M less.
Analysts await Puma Biotechnology Inc (NYSE:PBYI) to report earnings on March, 6. They expect $-2.02 EPS, down 6.32% or $0.12 from last year’s $-1.9 per share. After $-2.02 actual EPS reported by Puma Biotechnology Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Puma Biotechnology Inc (NYSE:PBYI) Ratings Coverage
Out of 6 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Puma Biotechnology Inc has been the topic of 13 analyst reports since August 27, 2015 according to StockzIntelligence Inc. Stifel Nicolaus upgraded the shares of PBYI in a report on Wednesday, September 21 to “Buy” rating. Citigroup initiated the shares of PBYI in a report on Thursday, September 3 with “Neutral” rating. The stock of Puma Biotechnology Inc (NYSE:PBYI) earned “Buy” rating by UBS on Monday, April 11. Credit Suisse maintained it with “Outperform” rating and $50 target price in Tuesday, March 29 report. The firm has “Buy” rating by Citigroup given on Tuesday, March 29. JP Morgan initiated the stock with “Overweight” rating in Thursday, August 27 report. The firm earned “Sector Perform” rating on Tuesday, March 29 by RBC Capital Markets. The stock has “Outperform” rating given by Credit Suisse on Thursday, January 21. The stock has “Buy” rating given by Citigroup on Monday, December 14. JP Morgan maintained the stock with “Overweight” rating in Tuesday, March 29 report.
According to Zacks Investment Research, “Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancer and gastric cancer and PB272 (neratinib intravenous) for the treatment of patients with advanced cancer. Puma Biotechnology, Inc. is headquartered in Los Angeles, California.”
Insitutional Activity: The institutional sentiment increased to 1.49 in Q2 2016. Its up 0.28, from 1.21 in 2016Q1. The ratio improved, as 24 funds sold all Puma Biotechnology Inc shares owned while 24 reduced positions. 18 funds bought stakes while 40 increased positions. They now own 31.26 million shares or 4.53% more from 29.91 million shares in 2016Q1.
Rock Springs Management Lp has 33,000 shares for 0.07% of their US portfolio. New York State Common Retirement Fund accumulated 0% or 57,300 shares. Metropolitan Life Insurance Ny reported 18,371 shares or 0% of all its holdings. California Employees Retirement holds 0% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI) for 42,400 shares. Clough Ptnrs Ltd Partnership has 246,600 shares for 0.39% of their US portfolio. Canada Pension Plan Invest Board, a Ontario – Canada-based fund reported 10,900 shares. Wellington Mgmt Grp Llp accumulated 0% or 12,623 shares. Voya Investment Management Limited Liability Corp last reported 10,633 shares in the company. Quantitative Invest Mgmt Lc holds 14,300 shares or 0.02% of its portfolio. D E Shaw Inc last reported 0.01% of its portfolio in the stock. Jpmorgan Chase & last reported 231,875 shares in the company. Checchi Advisers Limited Com holds 0% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI) for 101 shares. Great West Life Assurance Can accumulated 3,009 shares or 0% of the stock. Franklin Street Advsrs Nc has 0.19% invested in the company for 34,025 shares. Janus Mgmt Limited has 0.06% invested in the company for 2.54 million shares.
More important recent Puma Biotechnology Inc (NYSE:PBYI) news were published by: Fool.com which released: “Why Puma Biotechnology Inc. Sold Lower Today” on October 19, 2016, also Fool.com published article titled: “Why Puma Biotechnology Inc Roared Higher Today”, Fool.com published: “Why Puma Biotechnology, Inc. Stock Crashed 37% in March” on April 11, 2016. More interesting news about Puma Biotechnology Inc (NYSE:PBYI) was released by: Fool.com and their article: “Why Puma Biotechnology, Inc. Stock Soared 65.1% in July” with publication date: August 04, 2016.
PBYI Company Profile
Puma Biotechnology, Inc., incorporated on September 15, 2010, is a biopharmaceutical firm that focuses on the development and commercialization of products for the treatment of cancer. The Firm focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2, or HER2, positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.